Patents by Inventor Ming-Hsin Li

Ming-Hsin Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220227728
    Abstract: The present invention discloses a series of nuclear medicine tracers that are combined with brain microtubule-associated protein Tau targeting compounds to produce a group of compounds of nuclear medicine that can be utilized for imaging of microtubule-associated protein Tau. When the positrons released by the decay encounter the electrons of the cells in the sample, utilizing the positron decay characteristics of fluorine-18 or iodine-124 isotope to generate mutual destruction reactions, a pair of opposite gamma rays is formed which are imaged by positron emission tomography. The compounds can be applied for the in vivo detection of microtubule-associated protein Tau deposits in the brain. The invention provides a strategy for diagnosis of Alzheimer's disease and a method to measure the efficacy of therapeutic drugs targeting microtubule-associated protein Tau.
    Type: Application
    Filed: January 19, 2021
    Publication date: July 21, 2022
    Inventors: MING-HSIN LI, KAI-HUNG CHENG, SHENG-NAN LO, SHIH-WEI LO, YUAN-RUEI HUANG, JENN-TZONG CHEN
  • Patent number: 11369702
    Abstract: Disclosed herein are kits and methods for preparing radiopharmaceuticals. The kits and methods of the present disclosure can prepare the radiopharmaceuticals without using a heater and computer monitoring equipment. The kit includes a frozen crystal reaction vial, a reagent vial and a labeling holder, wherein the labeling holder contains a heating bag that can heat up to a high temperature of at least 95° C. by adding an aqueous solution.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: June 28, 2022
    Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH, ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN, R.O.C
    Inventors: Ming-Hsin Li, Shih-Wei Lo, Sheng-Nan Lo, Shih-Ying Lee, Su-Jung Chen
  • Patent number: 11369316
    Abstract: There is provided a system architecture including a PPG hardware module and a MEMS hardware module. The PPG hardware module processes PPG raw data, which is generally composed of analog signals or digital signals. The PPG hardware module filters the raw data for later digital calculation to, for example, find out frequency signals with higher peak values. The PPG hardware module then outputs the selected frequency signals to an MCU for heart rate calculation. The MEMS hardware module receives MEMS raw data from a motion detector made of MEMS elements. The MEMS raw data represents motion status of a user that could possibly affect the heart rate determination result. The MEMS hardware module filters the raw data for later digital calculation to find out frequency signals with higher peak values caused by motion.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: June 28, 2022
    Assignee: PIXART IMAGING INC.
    Inventors: Ren-Hau Gu, Yen-Min Chang, Ming-Chang Li, Chih-Hsin Lin
  • Publication number: 20220089574
    Abstract: The structure and preparation method of a compound D-L2(-B)-L1-A is disclosed, A is a physiologically and pharmacologically active molecule that physically binds to a specific biological molecule or receptor; L1 is a variable structure with the molecular connection activity at both ends connecting to A and L2; L2 is a variable structure, which has three-terminal molecular connection activity connecting to L1, D and B; B is a physiologically and pharmacologically active molecule that binds to albumin, changing the A molecule in the body cyclic characteristics; D is a polycarboxylic macrocyclic structure that binds to radioisotopes; D-L2(-B)-L1-A compound can be used to express chemokine receptor 4 (CXCR4) receptors on cells, tissues, and/or organs, and after binding with radionuclides, it is suitable for detection of CXCR4 protein binding in vitro, detection of CXCR4 cell binding in vitro or detection of CXCR4 expression in in vivo animal imaging.
    Type: Application
    Filed: September 22, 2020
    Publication date: March 24, 2022
    Inventors: MING-HSIN LI, SHENG-NAN LO, SHIH-WEI LO, SHIH-YING LEE, SU-JUNG CHEN, WEI-LIN LO, MING-WEI CHEN, YUAN-RUEI HUANG
  • Patent number: 11202577
    Abstract: A system and method for monitoring cardiovascular and brain functions in combination with a physiological detection device, which uses a smart wearable device to detect physiological data such as heart rate and pulse pressure of a user, and transmits the physiological data to an arithmetic function. An electronic device in which a preset function and a calculation formula are built in, and the physiological data can be converted into corresponding determination parameters to monitor the possibility and risk of cardiovascular diseases and neurodegenerative diseases.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: December 21, 2021
    Inventors: Ming-Hsin Li, Kai-Hung Cheng, Shih-Wei Lo
  • Publication number: 20210369878
    Abstract: Disclosed herein are kits and methods for preparing radiopharmaceuticals. The kits and methods of the present disclosure can prepare the radiopharmaceuticals without using a heater and computer monitoring equipment. The kit includes a frozen crystal reaction vial, a reagent vial and a labeling holder, wherein the labeling holder contains a heating bag that can heat up to a high temperature of at least 95° C. by adding an aqueous solution.
    Type: Application
    Filed: June 24, 2020
    Publication date: December 2, 2021
    Inventors: MING-HSIN LI, SHIH-WEI LO, SHENG-NAN LO, SHIH-YING LEE, SU-JUNG CHEN
  • Patent number: 11077217
    Abstract: The present invention provides a radioactive labeling method for neuropeptide Y (NPY) compound and a mammalian diagnostic radioactive targeting medicine with NPY peptide being modified at position 27th to 36th, and after binding with the chelating agent and labeling the radiation nucleus 66Ga67Ga68Ga177Lu or 111In to provide a radioactive targeting medicine for multi-type breast cancer diagnosis and treatment.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: August 3, 2021
    Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH, ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN
    Inventors: Ming-Hsin Li, Su-Jung Chen, Ming-Wei Chen, Yuan-Ruei Huang, Shih-Ying Lee, Chun-Fang Feng, Sheng-Nan Lo, Chih-Hsien Chang
  • Publication number: 20210121585
    Abstract: The invention features a novel precursor provided for radioisotope labeling with ligands for specific binding of prostate-specific membrane antigen (PSMA) for prostate cancer diagnosis and treatment, and the pharmacophore of a PSMA inhibitor composed of three molecules of glutamic acid, urea and lysine is provided with three variable linkers based on pharmacological activity of the PSMA inhibitor for labeling with radioactive nucleus Ga-67, Ga-68, In-111, Lu-177, Cu-64, or Y-90 through a chelating agent for imaging analysis of human tumor models of prostate cancer and serving as a PSMA-targeted radioligand therapy for prostate cancer diseases.
    Type: Application
    Filed: October 25, 2019
    Publication date: April 29, 2021
    Inventors: MING-HSIN LI, Sheng-Nan Lo, Shih-Wei Lo, Shih-Ying Lee, Su-Jung Chen, Shih-Min Wang, Ming-Wei Chen, Wei-Lin Lo
  • Publication number: 20210121074
    Abstract: A system and method for monitoring cardiovascular and brain functions in combination with a physiological detection device, which uses a smart wearable device to detect physiological data such as heart rate and pulse pressure of a user, and transmits the physiological data to an arithmetic function. An electronic device in which a preset function and a calculation formula are built in, and the physiological data can be converted into corresponding determination parameters to monitor the possibility and risk of cardiovascular diseases and neurodegenerative diseases.
    Type: Application
    Filed: October 28, 2019
    Publication date: April 29, 2021
    Inventors: MING-HSIN LI, KAI-HUNG CHENG, SHIH-WEI LO
  • Publication number: 20200237938
    Abstract: The present invention provides a radioactive labeling method for neuropeptide Y (NPY) compound and a mammalian diagnostic radioactive targeting medicine with NPY peptide being modified at position 27th to 36th, and after binding with the chelating agent and labeling the radiation nucleus 66Ga, 67Ga, 68Ga, 177Lu or 111In to provide a radioactive targeting medicine for multi-type breast cancer diagnosis and treatment.
    Type: Application
    Filed: December 11, 2018
    Publication date: July 30, 2020
    Inventors: Ming-Hsin Li, Su-Jung Chen, Ming-Wei Chen, Yuan-Ruei Huang, Shih-Ying Lee, Chun-Fang Feng, Sheng-Nan Lo, Chih-Hsien Chang
  • Publication number: 20200129646
    Abstract: A radioactive labeled long-acting peptide-targeting pharmaceutical and production method, in which the peptide targeted pharmaceutical is firstly dissolved in a solution, followed by labeling the radioactive at a high temperature, and the dosage of the pharmaceutical with radioactive labeling is expected to be reduced and labeling efficiency is improved, and no further purification by filtration is required, which shortens the preparation process and reduces personnel exposure in the working environment. The radioactive labeled long-acting peptide-targeting pharmaceutical can increase the specific binding capacity of tumors and reduce the non-specific accumulation in normal tissues. It can be applied to the field of tumor and nuclear medicine for diagnosis and treatment of tumors and/or tumor metastases with efficacy and precision treatment.
    Type: Application
    Filed: October 31, 2018
    Publication date: April 30, 2020
    Inventors: Ming-Hsin Li, Chih-Hsien Chang, Su-Jung Chen, Shih-Ying Lee, Sheng-Nan Lo, Ming-Wei Chen, Yuan-Ruei Huang, Chun-Fang Feng, Shih-Wei Lo, Cheng-Hui Chuang
  • Publication number: 20200078478
    Abstract: A PSMA targeting peptide derivative for radiotherapy, which is a structural molecule developed for diagnosis or treatment of prostate cancer, as prostate-specific membrane antigen (PSMA) is a protein present on the surface of healthy prostate cells, which is often at a high level of expression on the surface of prostate cancer cells, and the molecular composition of PSMA inhibitor is mainly composed of glutamic acid, urea and lysine, in addition to the linker of the present invention, PSMA inhibitor can be combined with a chelating agent and truncated Evans Blue, which can be labeled with radionuclides Ga-67, Ga-68, In-111, Lu-177, Cu-64 or Y-90, used for image analysis and analysis of human prostate cancer tumor pattern as a new PSMA targeting peptide receptor radionuclide therapy (PRRT), and which has a longer half-life in vivo and is featured by specific binding of PSMA for radiotherapy diagnosis or treatment.
    Type: Application
    Filed: September 10, 2018
    Publication date: March 12, 2020
    Inventors: Ming-Hsin Li, Ming-Wei Chen, Shin-Min Wang, Shih-Wei Lo, Chun-Fang Feng, Cheng-Hui Chuang, Sheng-Nan Lo
  • Patent number: 10507250
    Abstract: Method provided for labeling a nuclear medicine for imaging tracing, comprising a labeling precursor of the HDAC inhibitor BNL-26 (C22H23N3O) and the derivatives that are separated into two classes. The first class comprises a BNL-26 (C22H23N3O) and derivatives BNL-26a (C21H21N3O), BNL-26b (C22H22N2O), and other compounds of the labeling precursors which are categorized into two parts, the first part includes BNL-26-CH2CH2OTs (C31H33N3O4S), BNL-26a-CH2CH2OTs (C30H31N3O4S), and BNL-26b-CH2CH2OTs (C31H32N2O4S), which provides labeling precursor through —CH2CH2OTs structure, and the second part includes pre-BNL-26 (C28H34N3O3B), pre-BNL-26a (C27H32N3O3B), pre-BNL-26b (C28H33N2O3B), which provides labeling precursor through 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl structure. The second class includes BNL-26 (C22H23N3O) indole/indoline, which provides a series of derivative labeling precursors derived from a secondary amide bond.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: December 17, 2019
    Assignee: Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan
    Inventors: Ming-Hsin Li, Chyng-Yann Shiue, Han-Chih Chang, Chun-Fang Feng
  • Publication number: 20190076552
    Abstract: Method provided for labeling a nuclear medicine for imaging tracing, comprising a labeling precursor of the HDAC inhibitor BNL-26 (C22H23N3O) and the derivatives that are separated into two classes. The first class comprises a BNL-26 (C22H23N3O) and derivatives BNL-26a (C21H21N3O), BNL-26b (C22H22N2O), and other compounds of the labeling precursors which are categorized into two parts, the first part includes BNL-26-CH2CH2OTs (C31H33N3O4S), BNL-26a-CH2CH2OTs (C30H31N3O4S), and BNL-26b-CH2CH2OTs (C31H32N2O4S), which provides labeling precursor through —CH2CH2OTs structure, and the second part includes pre-BNL-26 (C28H34N3O3B), pre-BNL-26a (C27H32N3O3B), pre-BNL-26b (C28H33N2O3B), which provides labeling precursor through 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl structure. The second class includes BNL-26 (C22H23N3O) indole/indoline, which provides a series of derivative labeling precursors derived from a secondary amide bond.
    Type: Application
    Filed: September 8, 2017
    Publication date: March 14, 2019
    Inventors: Ming-Hsin Li, Chyng-Yann Shiue, Han-Chih Chang, Chun-Fang Feng
  • Patent number: 10005727
    Abstract: The present invention relates to a group of compounds for nuclear medicine imaging through F-18 labeled histone acetylation inhibitors (HDACi) of indole or indoline benzoyl amine and its derivatives, and provides a series of nuclear medicine imaging agents that bind with HDAC overexpression in vivo for diagnosis of malignant tumors discovered in the nuclear medicine imaging tracing.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: June 26, 2018
    Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL EXECUTIVE YUAN
    Inventors: Ming-Hsin Li, Chyng-Yann Shiue, Han-Chih Chang, Chun-Fang Feng
  • Publication number: 20180099933
    Abstract: The present invention relates to a group of compounds for nuclear medicine imaging through F-18 labeled histone acetylation inhibitors (HDACi) of indole or indoline benzoyl amine and its derivatives, and provides a series of nuclear medicine imaging agents that bind with HDAC overexpression in vivo for diagnosis of malignant tumors discovered in the nuclear medicine imaging tracing.
    Type: Application
    Filed: October 6, 2016
    Publication date: April 12, 2018
    Inventors: MING-HSIN LI, Chyng-Yann Shiue, Han-Chih Chang, Chun-Fang Feng
  • Publication number: 20170319723
    Abstract: Disclosed herein is a radioimmune complex comprising an epidermal growth factor receptor (EGFR)-targeted antibody and a radioactive isotope of rhenium labeled thereon. The EGFR-targeted antibody is cetuximab or panitumumab.
    Type: Application
    Filed: May 3, 2017
    Publication date: November 9, 2017
    Inventors: WAN-I KUO, KAI-HUNG CHENG, YI-SHU HUANG, SHENG-NAN LO, YA-JEN CHANG, TSUNG-TSE WU, WEI-CHUAN HSU, MING-HSIN LI, CHIH-HSIEN CHANG
  • Patent number: 9707521
    Abstract: An automated test apparatus for risk and integrity testing for pharmaceutical filtration membranes, including at least the following components: a liquid injection inlet, a pump, a fluid pressure gauge, a gas pressure gauge, a plurality of solenoid valves, a plurality of membranes, a gas pressure regulator valve, a pharmaceutical product bottle, and a bubble generation bottle. The automated test apparatus of the present invention is controlled by computer software in connection with an automatic pharmaceutical synthesis apparatus for automated testing. In use of the automated test apparatus of the present invention, it needs only to start the operating system of the automated test apparatus for membrane risk and integrity test after the completion of the automatic pharmaceutical synthesis. The membrane risk and integrity test can be accomplished in a short time by measuring pressures of gas and liquid with pressure gauges deposed online concurrently.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: July 18, 2017
    Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH
    Inventors: Ming-Hsin Li, Shu-Pei Chiu, Chih-Hsien Chang, Te-Wei Lee
  • Publication number: 20170110211
    Abstract: A method to produce a high-purity Zr-89 on a solid target through physical irradiation and measurement by selecting a target Barn value of the cross-sectional area of nuclear reaction, drawing a horizontal line to intersect at two points on the function diagram curve and drawing a vertical line downward from each of the two points intersecting at X-axis to obtain incident energy values at the two intersecting points on the X-axis, and followed by plotting an attenuation function diagram curve of penetration depth versus incident energy of Y-89(p,n)Zr-89, selecting an attenuation function diagram curve and a minimum attenuation position of the selected attenuation function diagram curve in correspondence to the incident energy in the interval of incident energy absorption range to obtain an optimal plating thickness value on the solid target.
    Type: Application
    Filed: October 14, 2015
    Publication date: April 20, 2017
    Inventors: Ming-Hsin LI, Ting-Shien DUH, Wuu-Jyh LIN, Han-Hsiang CHU
  • Patent number: 9603950
    Abstract: A method of synthesizing a compound of imaging agent with HDAC (histone deacetylase) inhibitor consists of two parts, the first part of the method is to provide the inhibitor of HDAC with a compound of imaging agent that includes HDAC inhibitor BNL-26 (C22H23N3O) and its analogs to be labeled with radionuclide F-18, producing a series of new nuclear medicine tracers: BNL-26-CH2CH218F, BNL-26a-CH2CH218FF, BNL-26b-CH2CH218F, BNL-26c-CH2CH218F and BNL-26d-CH2CH218F. These nuclear medicine with imaging agents can be used as a tracer in vivo binding to over-expression HDAC and produce a HDAC nuclear medicine imaging effect to serve for clinical diagnosis. The second part of the method is to provide a slightly adjusted a structural framework of BNL-26 and use pyridine to substitute the benzene ring of the BNL-26 structure, and then synthesize with other substituent to produce a series of additional 30 more HDAC inhibitors, named from Iner-1 to Iner-30 compounds.
    Type: Grant
    Filed: October 25, 2015
    Date of Patent: March 28, 2017
    Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH
    Inventors: Ming-Hsin Li, Chyng-Yann Shiue, Han-Chih Chang, Han-Hsiang Chu